Hypothesis: Anorexia and cancer cachexia produce significant loss of adipose tissue and muscle mass and eventually reduce survival in cancer patients. Study design: This phase II study was conducted to assess the efficacy and the safety of an herbal decoction with Astragali Radix in patients with anorexia in advanced cancer. Methods: All patients with histologic evidence of an incurable malignancy had a weight loss of at least 5% during the preceding 6 months and a patient-estimated severe anorexia. The herbal decoction was administered 30 minutes after meals, three times a day for 3 weeks. The score of appetite, body weight, the cytokines, IL-1b, IL-6, TNF-a, and anthropometric measurements were assessed. For the assessment of anorexia, a visual analog scale (VAS: 0 mm = no anorexia, 100 mm = maximal anorexia) was used. . The mean age was 59.8 years old. The change in anorexia from baseline with the herbal decoction was significantly different and anorexia was improved (anorexia VAS score, 60mm vs. 40mm, p = 0.008). The mean value of the maximal body weight was 55.6 kg and differed significantly from the 54.6 kg at baseline (p = 0.009). Changes in cytokine levels and anthropometric measurements from baseline to the 3rd week were not significant. All toxicities were manageable. Conclusion: Appetite and body weight were improved with the herbal decoction. This herbal decoction shows some potential for management of cancer-related anorexia.
Introduction
Anorexia is a common symptom in cancer patients. About 40% of patients have anorexia at diagnosis and up to 80% show anorexia as the disease progresses. 1 Anorexia and cancer cachexia show significant loss of body weight, 2,3 muscle mass, and adipose tissue, and eventually reduce performance status, survival, and quality of life in cancer patients. [4] [5] [6] [7] [8] [9] The main causes of anorexia are metabolic derangements, including the production of lactate and the release of serotonin and cytokines. [10] [11] [12] [13] Cytokines, such as IL (interleukin)-1b, IL-6, and tumor necrosis factor (TNF)-a, are produced by the tumor or host immune system. Anorexia may occur not only by direct interaction of cytokines with serotonin but also by delayed gastric emptying through cytokines. [14] [15] [16] [17] [18] [19] For generating adenosine triphosphate (ATP), the process of gluconeogenesis from lactate to glucose in liver is energy losing, 20, 21 and eventually anorexia leads to cancer cachexia. Some drugs, namely, corticosteroids, progestational agents, including megestrol acetate, cannabinoids, serotonin antagonists, and prokinetic agents, can help control anorexia. These agents improve appetite, increase body weight, and may improve overall health. [22] [23] [24] [25] [26] [27] [28] [29] [30] However, variability from 10% to 50% of responses and side effects such as edema limit their use. Few reports show improvements in survival.
Complementary and alternative medicines can help treat cancer-related and treatment-related symptoms. The current herbal decoction, which includes Astragali Radix, [31] [32] [33] [34] Atractylodis Rhizoma Alba, Hoelen, [35] [36] [37] [38] Pinelliae Tuber, Citri Unshiu Pericarpium, 39 Agastachis Herba, 40 Alismatis Rhizoma, Plantaginis Semen, 41 Spatholobi Caulis, 42 Zizyphi Fructus, Rhynchosia Nulubilis, Crataegi Fructus, Galli Stomachichum Corium, and Glycyrrhizae Radix, is an immune modulator, is renoprotective, reduces lactate dehydrogenase, and increases gastrointestinal function. [43] [44] [45] [46] This mixture has been developed to improve gastrointestinal function and modulate the immune system to treat anorexia.
This phase II study was conducted to assess the efficacy and the safety of this herbal decoction in improving appetite, body weight, and changing cytokine levels in cancer patients with anorexia.
Methods Overview
This phase II study was conducted by a single institute, the East-West Neomedical Center at Kyung Hee University from January, 2007 to January, 2009. All patients were histopathologically diagnosed with incurable advanced cancer at our institute. The current study was designed to enroll 30 patients, but was closed after only 11 patients because of the long recruitment time for patients who refused megestrol acetate. The current study was a prospective phase II clinical trial.
Patients
Eligibility criteria were as follows: Adult patients (older than 18 years of age) with histologic evidence of an incurable malignancy were eligible for study participation. Megesterol acetate was not effective in these patients, was refused, or not given because of tense ascites. Patients had an estimated life expectancy of more than 2 months and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2. Patients had a weight loss of at least 5% during the preceding 6 months and/or a patient-estimated severe anorexia (visual analog scale [VAS]: >50 mm) that were current problems for them. Use of chemotherapy or radiation therapy was permitted throughout the study period. Exclusion criteria included the use of tube feedings or parenteral nutrition, simultaneous treatment with adrenal corticosteroids (except for short-term dexamethasone during chemotherapy), androgens, progestational agents, or other appetite stimulants, brain metastasis, pregnancy or lactation, and mechanical obstruction of the alimentary tract. Edematous status, pleural effusion, and ascites were not exclusion criteria. All patients signed written informed consent to participate in the study. This study protocol was approved by the university institutional review board.
Prescription of the Herbal Decoction
The herbal decoction consisted of Astragali Radix 24 g/d, Atractylodis Rhizoma Alba 12 g/d, Hoelen 12 g/d, Pinelliae Tuber 12 g/d, Citri Unshiu Pericarpium 12 g/d, Agastachis Herba 8 g/d, Alismatis Rhizoma 12 g/d, Plantaginis Semen 8 g/d, Spatholobi Caulis 16 g/d, Zizyphi Fructus 12 g/d, Rhynchosia Nulubilis 12 g/d, Glycyrrhizae Radix 8 g/d, Crataegi Fructus 8 g/d, and Galli Stomachichum Corium 8 g/d. Astragali Radix, Citri Unshiu Pericarpium, Agastachis Herba, Alismatis Rhizoma, Zizyphi Fructus, Rhynchosia Nulubilis, Crataegi Fructus, and Galli Stomachichum Corium were obtained from the Republic of Korea and Glycyrrhizae Radix, Spatholobi Caulis, Pinelliae Tuber, Hoelen, Atractylodis Rhizoma Alba, and Plantaginis Semen from China. The herbal decoction was made in the hospital pharmacy every week and delivered to enrolled patients. The herbal decoction with 4.6 L of water was boiled for 2.5 hours at 102°C to 103°C. A 120 cm 3 pouch was taken as scheduled. The herbal decoction was administered 30 minutes after meals, 3 times a day for 3 weeks. This prescription was stopped for treatment refusal, the aggravation of anorexia or weight loss in the middle of therapy, or physician's decision.
Outcome Measures of Appetite
Assessments of appetite were performed at baseline and then weekly until the termination of the study. A primary end point was appetite change during the study period from baseline with a VAS (0 mm = no anorexia, 100 mm = maximal anorexia). 47 The Measurement of IL-1b, IL-6, and TNF-a
To analyze the level of the cytokines, IL-1b, IL-6, and TNF-a, the assay employed the quantitative sandwich enzyme immunoassay technique with serum. The assay was performed in the Department of Laboratory Medicine of East-West Neomedical Center, Kyung Hee University. A monoclonal antibody specific for IL-1b (Quantikine, R&D System, Inc., Minneapolis, MN), IL-6 (Quantikine, R&D System, Inc., Minneapolis, MN), and TNF-a (Quantikine, R&D system, Inc., Minneapolis, MN), had been precoated onto a microplate. Standards and samples are pipetted into the wells and any cytokine present is bound by the immobilized antibody. After washing away any unbounded substances, an enzyme-linked polyclonal antibody is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color developed in proportion to the amount of each cytokine. Color development is stopped and the intensity of the color is measured. The optical density of each well is determined within 30 minutes using a microplate reader set to 450 nm.
Follow-up
A history and physical examination, which included body weight and height measurement, were performed at study entry. The VAS anorexia score and body weight were assessed at baseline and then weekly for 3 weeks. Skinfold thickness was measured as the anthropometric measure at baseline and the third week at 3 points: triceps, subscapula, and suprailiac.
For baseline laboratory evaluation, complete blood count/ differential count (CBC/DC), liver function test, renal function test, electrolytes, including calcium, lactate, lactate dehydrogenase (LDH), urinalysis, electrocardiography, and chest X-ray were performed. For toxicity evaluation, CBC/ DC, liver function test, renal function test, and electrolytes, including calcium, were examined weekly. For analyzing anorexia-related factors, IL-1b, IL-6, TNF-a, and lactate were tested at baseline and at the termination of treatment.
Response assessment of tumor status was performed about every 2 months or whenever clinically indicated by chest and/or abdominal computed tomography. The responses were assessed according to the response evaluation criteria in solid tumors (RECIST) guidelines. 48 The definitions of the RECIST used to determine objective tumor response for target lesions with the measurement of the longest diameter only for all target lesions: complete response-the disappearance of all target lesions; partial response-at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter; progressive disease-at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions; stable disease-neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started. The definitions of the criteria used to determine the objective tumor response for nontarget lesions: complete response-the disappearance of all nontarget lesions and normalization of tumor marker level; incomplete response/ stable disease-the persistence of one or more nontarget lesion(s) and/or the maintenance of tumor marker level above the normal limits; and progressive disease-the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions. Nontarget lesions considered to be truly nonmeasurable include the following: bone lesions, leptomeningeal disease, ascites, and pleural/ pericardial effusion.
Statistical Analyses
The primary end point of the current study was to evaluate the efficacy of the herbal decoction for improving anorexia. Secondary end points were to analyze the change in body weight and cytokines. The Wilcoxon signed-rank test was used to analyze prevariables and postvariables, with Fisher's exact test used to analyze the categorical variables. The Mann-Whitney test was used to analyze the continuous variables. All hypothesis testing was performed using a 2-sided test and a 5% type I error rate. Sample size was determined with a 15% difference in appetite improvement and 80% power by the minimax method. A sample size of 27 patients was sufficient, with a final target of 30 patients, including 10% dropouts. However, we accrued only 11 patients for this study and closed it early because of the extended recruitment process.
Results

Patient Characteristics
A total of 11 patients were recruited from January, 2007 to January, 2009 ( Table 1 ). All patients had incurable, advanced disease except one patient who had been in the middle of adjuvant chemotherapy after curative gastrectomy. All patients were eligible for the evaluation of efficacy and safety of the herbal decoction. The mean age was 59.8 years, ranging from 42 to 76 years. In all, 8 (72.7%) patients were male. Half of the patients had ECOG PS 2. Megestrol acetate could not be administered because of lack of responsiveness for 3 patients, ascites and pleural effusion for 3 patients, and refusal for 4 patients. The types of cancer were 7 lung cancers, 3 gastric cancers, and 1 colorectal cancer. The common metastatic lesions were liver (36%) and bone (36%). Pleural effusion and peritoneal carcinomatosis were shown in 5 patients (45%). All patients had previously received chemotherapy except 1 patient who had been diagnosed with advanced gastric cancer. The herbal decoction was administered with concomitant chemotherapy or in the middle of a chemotherapy cycle in 5 (45%) out of 11 patients.
Effect on Appetite
The VAS anorexia scores before and after the herbal decoction were 60 and 40 mm, respectively. The change from baseline to the best VAS anorexia score was significantly improved (P = .008; Table 2 ). VAS anorexia scores improved in 9 of 11 patients, with a response rate of 81%. In 8 (72.7%) of 11 patients, VAS anorexia scores were improved by 20 mm or more.
Effect on Body Weight
The mean maximum body weight during therapy was 55.6 kg from 54.6 kg at baseline (P = .009; Table 3 ). Overall, 6 (55%) of 11 patients showed improvements in both anorexia and body weight at the third week. The correlation of the improvement in anorexia and body weight was analyzed at the best point (g = .797, P = .003) and was significantly positive. A positive correlation of the improvement in body weight at the most improved point of anorexia and the anorexia was also observed (g = .765, P = .06).
Effect on Anthropometric Measures
The changes in skinfold thickness of the triceps, subscapula, and suprailiac did not significantly change (mean ± SD of baseline vs third week, 12.1 ± 5.8 vs 13.6 ± 6.8 mm, P = .182; 16.6 ± 7.4 mm vs 16.3 ± 7.9 mm, P = .859; and 24.8 ± 9.5 mm vs 23.1 ± 10.2 mm, P = .477).
Effect on Cytokines and Lactate
IL-1b, IL-6, and TNF-a, which are the main causes of cancer anorexia and cachexia, were checked at baseline and the third week, but did not significantly change ( Table 4 ). The levels of lactate and LDH, which were checked at the same time as the cytokines, were significantly worse at the third week (Table 4 ).
Treatment Delivery
The full treatment of the herbal decoction was administered to 8 patients. For 3 patients, the herbal decoction was administered for about 2 weeks. Treatment was stopped because of the toxicity of concomitant chemotherapy in 1 patient and disease progression in 2 patients who had experienced intractable hypercalcemia and a physical obstruction of the gastrointestinal tract. Baseline score, mean ± SD (kg) 54.5 ± 10.8 The best score, mean ± SD (kg) 55.6 ± 11.6 The third week score, mean ± SD (kg) 54.9 ± 11.8 From best to baseline P = .009 b From third week to baseline P = .306 b a A positive correlation of the improvement in body weight at the most improved point of anorexia and the degree of anorexia was also observed (g = 0.765, P = .06).
b
Wilcoxon signed-rank test.
Safety
All patients were evaluated for toxicity, including physical examination and laboratory findings every week during treatment. Grade 1/2 diarrhea occurred in 2 patients. Grade 1 dyspepsia occurred in 2 patients. Grade 1 alanine transaminase (ALT) abnormality was observed in 1 patient. Among hematologic toxicities, grade 2 neutropenia and grade 2 anemia developed in 2 patients who had received concomitant chemotherapy and had been in the middle of a chemotherapy cycle. The neutropenia and anemia were because of the administered chemotherapy rather than the herbal decoction.
Discussion
Various cytokines, TNF-a, IL-6, and IL-1b, lactate, serotonin, and neurohormonal substances produced by tumors can induce cancer anorexia and modulate the immune response. [14] [15] [16] [17] [18] [19] Compared with the mechanism of simple starvation, the altered metabolism and related substances of cancer anorexia and cachexia syndrome cause a loss of lean body mass by using protein as an energy source. 12, 20, 21 Unintentional body weight loss is related to increased morbidity and mortality. [7] [8] [9] Moreover, body weight loss with cancer decreases performance status, the response to therapy, and survival. [7] [8] [9] We evaluated the efficacy and safety of an herbal decoction with Astragali Radix as the primary component. Astragali Radix improved anorexia and fatigue in AIDS patients. 32 Astragali Radix protects cells against hypoxia by inhibiting the release of LDH, which is increased in cancer anorexia. 31 Hoelen, Citri Unshiu Pericarpium, Agastachis Herba, Spatholobi Caulis, Rhynchosia Nulubilis and Glycyrrhizae Radix have anti-inflammatory activity as immune modulators. [35] [36] [37] [38] [39] [40] Hoelen blocks selective serotonin reuptake inhibitors (SSRIs), which can induce anorexia with serotonin, and Pinelliae inhibits the vomiting center in animal models. 43, 44 Appetite, body weight, and survival are endpoints for anorexia management in clinical trials. Studies with prednisolone and megestrol acetate showed improvements in anorexia and body weight, but appetite can also improve without any gains in body weight. We observed improvements in anorexia and body weight, with 3 patients having third space fluid, ascites, and pleural effusion ( Table 5) . Two patients with ascites had progressive disease and the patient with pleural effusion had stable disease. In 1 patient with ascites, the anorexia score and weight improved without increasing ascites. In the other patient with ascites, the anorexia was improved but weight decreased with disease progression. In the patient with stationary pleural effusion, weight gain was shown without improving anorexia. Weight gain was not associated with the aggravation of third space fluid, but with improving oral intake.
In the current study, although improvement in anorexia with the herbal decoction was shown, an increase in plasma lactate and LDH was observed ( Table 5 ). The causes of increase in lactate are the aerobic conditions, which are malignancy, diabetes mellitus, renal or hepatic failure, seizures, or drug/toxins, and secondary to poor tissue perfusions, which are circulatory insufficiency and severe anemia. An increase in plasma lactate was observed in 7 among 9 patients with improving anorexia. There were 3 patients with progressive disease status, 1 with diabetes mellitus and ischemic heart disease, and 1 with chemotherapy-related G2 anemia. Those factors might be the reasons why the level of lactate increased. LDH is a factor to be considered as a tumor marker. In 5 of 9 patients with improving anorexia, the level of LDH was increased. Three patients had progressive disease status. Increase in LDH could be partially interpreted as a tumor marker.
The current study has some limitations. First, this study enrolled only a small number of patients. Second, it was not a randomized study, and we thus cannot rule out a placebo effect. Third, there was the discrepancy between the anorexia VAS score and the change of cytokines. Cytokines were checked at baseline and the third week, whereas the anorexia VAS score was checked at baseline and weekly thereafter. Therefore, cytokine changes may have been missed. Otherwise, it is possible that the effect on anorexia was not mediated by cytokines but by the other factors, such as a placebo effect of being in the experiment, effect on taste, increased digestion capacity, and so on. Additionally, the study size may have been too small to detect changes in such a short period.
Conclusions
The current study evaluated the efficacy and safety of an herbal decoction for cancer-related anorexia in patients with advanced solid tumors. We observed that the herbal decoction improved appetite scores and body weight. Therefore, the herbal decoction shows some potential for management of cancer-related anorexia. Clinical trials with a larger population should be planned to confirm the efficacy of this herbal decoction.
